Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2011

View Archived Issues

CalciMedica begins phase I trial of CM-2489 for psoriasis

FDA grants orphan drug status to MGN-4893 in polycythemia vera

Phase I/II trial of panobinostat/bicalutamide combination in prostate cancer advances

IST5-002 shows promise in models of prostate cancer

MedTrust Online and Avantra partner to validate cancer biomarker assays

Brusatol suppresses development of resistance to chemotherapeutic agents in vivo

Gelsolin is a putative biomarker in subarachnoid hemorrhage

Fractalkine is a potential target for drugs for Parkinson's disease

TB Alliance presents agents for tuberculosis and protozoal infections

Kancera acquires iNovacia

Omeros expands exclusive PDE7 inhibitor license from Daiichi Sankyo

Infinity Pharma begins phase II portion of IPI-926 trial in pancreatic cancer

IRM discloses new GPR119 receptor modulators

Regeneron submits BLA for VEGF Trap-Eye for wet AMD

Merck & Co. claims new activators of glycoprotein hormone FSH receptor

Angiochem receives NBTS innovation award for development of new brain cancer treatments

Kyowa Hakko Kirin to acquire ProStrakan

Encouraging phase IIa data reported on Cx-601 for perianal fistulas in patients with Crohn's disease

GSK presents novel GlyT1 inhibitors

AstraZeneca and Pulmagen present dual-acting agents for respiratory disorders

Gilead Sciences to acquire Calistoga Pharmaceuticals

Sanofi Pasteur and International Vaccine Institute join forces against dengue fever

Chugai's anticancer agent Xeloda approved for additional indication in Japan

Theratechnologies to launch new clinical program for tesamorelin in COPD-associated muscle wasting

Forest Labs enters into definitive merger agreement to acquire Clinical Data

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...